Dr. Tareq Abadl: What If Blood Matching Went Deeper than Just ABO and Rh?
Dr. Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Precision Transfusion Medicine
What if blood matching went deeper than just ABO and Rh?
Molecular blood-group genotyping analyzes a patient’s blood-group genes to predict dozens of clinically significant antigens — transforming modern transfusion practice.
1. Deeper and Safer Matching
Genotyping identifies variant and weak alleles that routine serology may miss, such as:
Weak/Partial D variants
Rh, Kell, Kidd, Duffy, and MNS variants
This reduces the risk of alloimmunization, especially in patients requiring chronic transfusions (e.g., sickle cell disease, thalassemia).
2. Faster Compatible Unit Selection
Creating a genotyped donor registry allows rapid identification of best-matched units, which is crucial for patients with:
Multiple alloantibodies
Rare or complex phenotypes
3. Improved Antenatal Care
Molecular typing enhances:
Prediction of fetal antigen status
Early assessment of hemolytic disease of the fetus and newborn (HDFN)
Guidance on monitoring and intervention
4. Practical Limitations
Genotyping is powerful but works alongside serology, not as a replacement:
It predicts antigen expression, which may not always equal phenotype
Results can be affected after allogeneic stem-cell transplant or recent transfusion
Use buccal swabs or pre-transfusion samples when needed
Requires proper quality control and expert interpretation
5. Better Donor Strategy and Inventory
Molecular typing helps:
Recruit and flag rare-donor phenotypes
Improve blood-bank inventory management
Provide safer, more reliable matching for high-risk patients
How You Can Act
For Transfusion Professionals:
Implement targeted genotyping for chronically transfused or alloimmunized patients.
For Blood Donors:
Join local rare-donor programs if available — you may save lives in ways only a few can.
Find more posts featuring Dr. Tareq Abadl on Hemostasis Today.
-
Jun 29, 2026, 20:09Mamta Soni: The Role of Anti-Xa Monitoring in Anticoagulation Management
-
Jun 29, 2026, 20:07Nita Radhakrishnan: Discussing Risks, Benefits, and Uncertainties in Hemoglobinopathy Care
-
Jun 29, 2026, 20:05Anisha Navkudkar: TMH Blood Centre Received the Ravi Reddy Award 2026 at ISBT Congress
-
Jun 29, 2026, 20:03Anirban Sen Gupta: Congratulations Christopher Delianides for a Fantastic Dissertation and Graduate Research Presentation
-
Jun 29, 2026, 20:01May Guo: Inhibiting Anti-PEG Antibody Binding With Randomized PEG
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice